BioXcel Therapeutics, Inc. (BTAI)

NASDAQ: BTAI · IEX Real-Time Price · USD
2.820
-0.060 (-2.08%)
At close: Mar 28, 2024, 4:00 PM
2.960
+0.140 (4.96%)
After-hours: Mar 28, 2024, 6:28 PM EDT

Company Description

BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology.

The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices.

Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia.

In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally innate immunity activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, a drug candidate to target aggression in dementia.

BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.

BioXcel Therapeutics, Inc.
BioXcel Therapeutics logo
Country United States
Founded 2017
IPO Date Mar 8, 2018
Industry Biotechnology
Sector Healthcare
Employees 74
CEO Dr. Vimal D. Mehta Ph.D.

Contact Details

Address:
555 Long Wharf Drive
New Haven, Connecticut 06511
United States
Phone 203-643-8060
Website bioxceltherapeutics.com

Stock Details

Ticker Symbol BTAI
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001720893
CUSIP Number 09075P105
ISIN Number US09075P1057
Employer ID 82-1386754
SIC Code 2834

Key Executives

Name Position
Dr. Vimal D. Mehta Ph.D. Founder, Chief Executive Officer, President, and Director
Javier Rodriguez Senior Vice President, Chief Legal Officer and Corporate Secretary
Matthew Wiley Senior Vice President and Chief Commercial Officer
Richard I. Steinhart MBA Senior Vice President and Chief Financial Officer
Dr. Frank D. Yocca Ph.D. Senior Vice President and Chief Scientific Officer
Dr. Vincent J. O'Neill B.Sc., M.D., M.R.C.P. Executive Vice President and Chief of Product Development and Medical Officer
Dr. Chetan D. Lathia Ph.D. Senior Vice President and Head of Translational Medicine, Clinical Pharmacology and Regulatory Affairs
Dr. Robert Risinger M.D. Chief Medical Officer - Neuroscience
Robert Scala Vice President of Commercial Operations and Launch Planning
Dr. Friso Postma Senior Director of Neuroscience and Artificial intelligence

Latest SEC Filings

Date Type Title
Mar 25, 2024 8-K Current Report
Mar 25, 2024 424B5 Filing
Mar 22, 2024 10-K Annual Report
Mar 12, 2024 8-K Current Report
Feb 14, 2024 8-K Current Report
Feb 12, 2024 8-K Current Report
Feb 9, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 8, 2024 424B5 Filing
Feb 8, 2024 8-K Current Report
Feb 8, 2024 8-K Current Report